Table 1. Relationship between blood lipids and clinicopathological features.
| Pathological features | Negative group (n=40) | Positive group (n=19) | P |
|---|---|---|---|
| Tumor size (cm) | |||
| ≤2 | 19 | 10 | 0.071 |
| 2–5 | 21 | 7 | |
| >5 | 0 | 2 | |
| Lymph metastasis | |||
| Negative | 20 | 4 | 0.034 |
| Positive | 20 | 15 | |
| Molecular classification | |||
| Luminal A/B | 31 | 13 | 0.227 |
| Basal-like | 4 | 5 | |
| HER2 overexpression | 5 | 1 | |
| Clinical stages | |||
| I | 10 | 4 | 0.593 |
| II | 24 | 10 | |
| III | 6 | 5 | |
| Histological grade | |||
| I–II | 25 | 14 | 0.396 |
| III | 15 | 5 | |
| HER2 | |||
| Negative | 22 | 16 | 0.029 |
| Positive | 18 | 3 | |
| Carcinoma embolus | |||
| Negative | 26 | 9 | 0.198 |
| Positive | 14 | 10 | |
| Ki-67 | |||
| ≤30 | 16 | 9 | 0.593 |
| >30 | 24 | 10 |
HER2, human epidermal growth factor receptor 2.